| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 10 | 10 | 10 | 10 | 1,000 |
| Sales Growth | unch | unch | unch | -99.00% | +2.04% |
| Net Income | -5,380 | -11,920 | 18,970 | 1,430 | 64,400 |
| Net Income Growth | +54.87% | -162.84% | +1,226.57% | -97.78% | +694.64% |
Pavmed Inc
(PAVM)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation and cardiovascular intervention. PAVmed Inc. is headquartered in New York City.
Fiscal Year End Date: 12/31